Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUDAFED 24 HOUR vs AFRINOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Afrinol is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors in the vascular smooth muscle of nasal blood vessels, causing vasoconstriction and reducing nasal congestion. It also has weak alpha-2 agonist activity.
Relief of nasal congestion associated with common cold, hay fever, and other upper respiratory allergies,Off-label: Eustachian tube congestion
Temporary relief of nasal congestion due to colds, hay fever, or other upper respiratory allergies.
120 mg orally every 24 hours (extended-release tablet).
Oral: 1 tablet (pseudoephedrine 120 mg, triprolidine 2.5 mg) every 12 hours; maximum 2 tablets per day.
Terminal elimination half-life 9-16 hours (mean 11 hours) in adults; prolonged in renal impairment (up to 24-30 hours in severe insufficiency); clinically relevant for dosing interval (every 24 hours)
9–11 hours in healthy adults; prolonged to 16–18 hours in hepatic cirrhosis and up to 20 hours in severe renal impairment. Clinical context: dosing interval typically 12 hours in normal renal function.
Primarily hepatic via N-demethylation to active metabolite (norpseudoephedrine); also undergoes oxidative metabolism. CYP450 enzymes involved include CYP2D6.
Primarily hepatic metabolism via oxidative deamination and glucuronidation; the major enzyme involved is monoamine oxidase (MAO).
Renal 70-90% unchanged; minor hepatic metabolism to inactive metabolites; biliary/fecal excretion negligible (<5%)
Renal (approximately 70–90% as unchanged drug and metabolites), with about 10% biliary/fecal elimination. Dose adjustment required in renal impairment (Cr Cl <30 m L/min).
Low, approximately 20-30%; primarily binds to albumin
80–90% bound to serum albumin and alpha-1-acid glycoprotein.
2.6-3.5 L/kg; suggests extensive tissue distribution (highly lipophilic)
4.0–5.0 L/kg. Indicates extensive tissue distribution, with concentrations exceeding plasma levels in lung, liver, kidney, and brain.
Oral: 100% (well absorbed); extended-release formulation designed for once-daily dosing
Oral: 40–50% (first-pass metabolism). Intranasal: 70–80% (systemic absorption variable). Intravenous: 100%.
GFR 30-50 m L/min: 120 mg every 24 hours; GFR <30 m L/min: not recommended.
Cr Cl 30-50 m L/min: prolong interval to every 18-24 hours; Cr Cl <30 m L/min: avoid use.
No adjustment necessary; monitor for adverse effects in Child-Pugh C.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, consider dose reduction; Child-Pugh C: avoid use.
Children 6-11 years: 60 mg orally every 24 hours (extended-release tablet).
Children 6-12 years: 1/2 tablet (pseudoephedrine 60 mg, triprolidine 1.25 mg) every 12 hours; maximum 1 tablet per day. Children <6 years: not recommended.
Start with 60 mg orally every 24 hours; increase gradually based on response and tolerability.
Start with 1/2 tablet (pseudoephedrine 60 mg, triprolidine 1.25 mg) every 12 hours; monitor for CNS effects, anticholinergic side effects, and hypertension.
None.
None.
May cause hypertension, palpitations, tachycardia, arrhythmias, and stroke; use with caution in patients with cardiovascular disease, hypertension, hyperthyroidism, diabetes, or prostatic hypertrophy; avoid in patients with severe hypertension or coronary artery disease; risk of drug dependence with long-term use; avoid use with MAOIs or within 14 days of MAOI therapy.
Hypertension, cardiovascular disease, hyperthyroidism, diabetes mellitus, increased intraocular pressure, prostatic hyperplasia; use caution in elderly patients; do not exceed recommended dosage.
Severe hypertension, coronary artery disease, narrow-angle glaucoma, urinary retention, concurrent MAOI therapy or within 14 days, hypersensitivity to pseudoephedrine.
Hypersensitivity to any component; concurrent use or recent use (within 14 days) of MAO inhibitors; severe hypertension or coronary artery disease.
Avoid high-tyramine foods (e.g., aged cheeses, cured meats, soy products) if taking MAOIs. Caffeine may increase stimulant effects. Alcohol may exacerbate CNS side effects.
Avoid excessive caffeine intake as it may increase stimulant effects. No significant food interactions known.
First trimester: No evidence of major malformations in human studies. Second and third trimesters: Potential for uterine vasoconstriction and reduced placental perfusion; may cause fetal tachycardia or arrhythmias. Use only if benefit outweighs risk.
Afrinol (pseudoephedrine) is generally considered low risk during pregnancy. First trimester: Some studies suggest a possible association with gastroschisis, but data are inconsistent. Second and third trimesters: Avoid due to risk of uterine vasoconstriction and potential fetal hypoxia, especially near term. Overall, FDA Pregnancy Category C.
Pseudoephedrine is excreted in breast milk (M/P ratio ~3.3). May reduce milk production. Use with caution; monitor infant for irritability and sleep disturbances.
Pseudoephedrine is excreted into breast milk in small amounts (M/P ratio approximately 2.6–3.5). Use with caution as it can reduce milk production and may cause irritability in the infant. A single dose is likely safe, but chronic use is not recommended.
No specific dose adjustment recommended. However, decreased gastrointestinal motility and increased plasma volume in pregnancy may alter absorption and distribution; use lowest effective dose for shortest duration.
No specific dose adjustments are established for pregnancy. However, due to increased plasma volume and renal clearance, the duration of action may be shorter. Use the lowest effective dose for the shortest duration, typically 60 mg every 4–6 hours (max 240 mg/day).
Contains pseudoephedrine HCl 240 mg extended-release. Contraindicated in severe hypertension, coronary artery disease, and MAOI use. Avoid alcohol; may cause insomnia, anxiety, or tachycardia. Advise against bedtime dosing.
AFRINOL contains oxymetazoline, an imidazoline sympathomimetic with alpha-adrenergic agonist activity. It causes vasoconstriction in nasal mucosa. Limit use to 3 days to avoid rhinitis medicamentosa. Avoid in patients with narrow-angle glaucoma, severe hypertension, or MAOI use. Onset is within minutes, duration up to 12 hours.
Do not crush or chew the tablet; swallow whole with water.,Do not take more than one tablet in 24 hours.,Avoid other products containing pseudoephedrine or other decongestants.,Discontinue if you experience palpitations, chest pain, or dizziness.,Consult a doctor before use if you have high blood pressure, heart disease, diabetes, or glaucoma.
Do not use for more than 3 consecutive days to avoid rebound congestion.,Do not share the bottle with others to prevent infection.,Do not exceed recommended dosage; use only 2-3 sprays per nostril every 10-12 hours as directed.,Avoid using if you have high blood pressure, heart disease, or glaucoma without consulting a doctor.,Consult a doctor if symptoms persist beyond 3 days or if you experience severe side effects like headache, rapid heartbeat, or dizziness.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUDAFED 24 HOUR vs AFRINOL, answered by our medical review team.
SUDAFED 24 HOUR is a Decongestant that works by Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.. AFRINOL is a Decongestant that works by Afrinol is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors in the vascular smooth muscle of nasal blood vessels, causing vasoconstriction and reducing nasal congestion. It also has weak alpha-2 agonist activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUDAFED 24 HOUR and AFRINOL depend on the specific clinical indication. These are both Decongestant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUDAFED 24 HOUR is: 120 mg orally every 24 hours (extended-release tablet).. The standard adult dose of AFRINOL is: Oral: 1 tablet (pseudoephedrine 120 mg, triprolidine 2.5 mg) every 12 hours; maximum 2 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUDAFED 24 HOUR and AFRINOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUDAFED 24 HOUR is classified as Category C. First trimester: No evidence of major malformations in human studies. Second and third trimesters: Potential for uterine vasoconstriction and reduced placental perfusion; may cause. AFRINOL is classified as Category C. Afrinol (pseudoephedrine) is generally considered low risk during pregnancy. First trimester: Some studies suggest a possible association with gastroschisis, but data are inconsist. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.